| Literature DB >> 24034366 |
York A Zausig, Daniel Chappell, Bernhard F Becker, Daniel Potschka, Hendrik Busse, Kathrin Nixdorf, Diane Bitzinger, Barbara Jacob, Matthias Jacob.
Abstract
INTRODUCTION: Recent data suggested an interaction between plasma constituents and the endothelial glycocalyx to be relevant for vascular barrier function. This might be negatively influenced by infusion solutions, depending on ionic composition, pH and binding properties. The present study evaluated such an influence of current artificial preparations.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24034366 PMCID: PMC4057311 DOI: 10.1186/cc12898
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Experimental protocols. Protocol 1: transudate formation (TF). Sample generation for assessing transudate formation and glycocalyx shedding in control (TF-Control) and study groups (TF-NaCl, TF-Ri-Ac, TF-6% HES, TF-10% HES, and TF-Gel). The same hearts were used to determine interstitial water content after the protocol, and in two additional cases in each group, for electron microscopy evaluation. Protocol 2: polymorphonuclear neutrophils (PMN). The intracoronary adhesion rates of PMN were determined in control (PMN-Control) and study groups (PMN-NaCl, PMN-Ri-Ac, PMN-6% HES, PMN-10% HES, and PMN-Gel) at the time indicated. Application and evaluation followed the detailed description given within the running text. Protocol 3: heart performance (HP). The determination of heart performance occurred in control (HP-Control) and study groups (HP-NaCl, HP-Ri-Ac, HP-6% HES, HP-10% HES, and HP-Gel) at the times indicated. For details, see Materials and methods.
Normal ranges of electrolyte, bicarbonate, phosphate and lactate in comparison to the composition of the studied solutions
| Plasma | NaCl | Ri-Ac | 6% HES | 10% HES | Gel | Unit of measurement | |
|---|---|---|---|---|---|---|---|
| Sodium | 137 to 147 | 154 | 130 | 130 | 130 | 144 | mmol/l |
| Potassium | 3.5 to 5.5 | NA | .5.4 | .5.5 | .5.5 | 5 | mmol/l |
| Magnesium | 0.8 to1.0 | NA | 1 | 1 | 1 | .1.5 | mmol/l |
| Calcium | 2.2 to 2.6 | NA | 0.9 | 1 | 1 | .2.5 | mmol/l |
| Chloride | 95 to 110 | 154 | 112 | 112.5 | 112.5 | 103 | mmol/l |
| Bicarbonate | 23 to 25 | NA | NA | NA | NA | NA | mmol/l |
| Phosphate | 0.8 to 1.6 | NA | NA | NA | NA | NA | mmol/l |
| Acetate | NA | NA | 27 | 27 | 27 | 27 | mmol/l |
| Lactate | 0.0 to 1.0 | NA | NA | NA | NA | NA | mmol/l |
| NA | NA | NA | 6 | 10 | NA | g% | |
| Gelatine | NA | NA | NA | NA | NA | 4 | g% |
| Theoretical osmolality | 280 to 300 | 308 | 276 | 277 | 277 | 283 | mosmol/kg H2O |
NaCl, isotonic saline; Ri-Ac, ringer's acetate; 6% and 10% HES: 6% and 10% hydroxyethyl starch in Ringer's acetate. NA (not applicable).
Figure 2Endothelial glycocalyx. Exemplary electron microscopy picture of an intact endothelial glycocalyx after perfusion under control conditions (TF-Control, left panel) and after intracoronary infusion of 6% hydroxyethyl starch (TF-6% HES, right panel).
Figure 3Vascular integrity. Transudate formation (all data expressed as mean ± SD; n = 6 for each group). Filled bars, basal measurement; open bars, second or study measurement. There were no significant differences among the basal measurements of all groups (analysis of variance (ANOVA): df = 5; F = 0.444; P = 0.814). *P <0.05 basal measurement versus study measurement (Student's paired t-test); +P <0.05 versus all other basal and second/study measurements; #P <0.05 versus all other basal and second/study measurements except study measurement of TF-10% HES; §P <0.05 versus all other basal and second/study measurements except TF-6% HES and TF-Gel (ANOVA: df = 5; F = 172,644; P = 0.000; pairwise post hoc test performed with Dunnett´s T3-test).
Figure 4Haemodynamic performance. Rate-pressure product (RPP, all data expressed as mean ± SD; n = 6 for each group). Filled bars, basal measurement; open bars, second or study measurement. *P <0.05 versus Control; #P <0.05 versus HP-NaCl (analysis of variance: df = 5; F = 29.361; P <0.001; pairwise post hoc testing performed with the Bonferroni correction).
Values measured within effective perfusate during study phase without (HP-Control) and with (HP-NaCl, HP-Ri-Ac, HP-6% HES, HP-10% HES and HP-Gel) infusion of respective preparation according to the study protocol
| HP-Control | HP-NaCl | HP-Ri-Ac | HP-6% HES | HP-10% HES | HP-Gel | Unit of measurement | |
|---|---|---|---|---|---|---|---|
| 139 ± 1 | 148 ± 2*# | 133 ± 2* | 134 ± 4* | 136 ± 2* | 136 ± 2* | mmol/l | |
| .3.78 ± 0.04 | .1.77 ± .0.05*# | .4.41 ± .0.09* | .4.46 ± .0.12* | .4.49 ± .0.09* | .4.21 ± .0.09* | mmol/l | |
| .1.86 ± 0.05 | .0.97 ± .0.04*# | .1.33 ± .0.02* | .1.39 ± .0.05* | .1.44 ± .0.04* | .1.49 ± .0.11* | mmol/l | |
| 269 ± 26 | 266 ± 34 | 256 ± 24 | 274 ± 16 | 276 ± 25 | 276 ± 5 | mosmol/l | |
| .7.43 ± 0.04 | .7.38 ± .0.06 | .7.33 ± .0.03* | .7.14 ± .0.04* | .7.08 ± .0.04* | .7.25 ± .0.03* |
Electrolyte concentrations, osmolarity and pH in perfusate, assessed in the delivering lines of the HP groups under basal conditions (HP-Control) and after having switched to infusion mode using the respective study solutions (HP-NaCl, HP-Ri-Ac, HP-6% HES, HP-10% HES, and HP-Gel). All data expressed in mean ± SD; n = 6 for each group; *P <0.001 versus HP-Control; #P <0.001 versus HP-Ri-Ac, HP-6% HES, HP-10% HES, and HP-Gel. HP, heart performance; NaCl, isotonic saline; Ri-Ac, ringer's acetate; 6% and 10% HES: 6% and 10% hydroxyethyl starch in Ringer's acetate.